​​​​​Thermo Fisher Scientific Inc TMO said that its COVID-19 diagnostic tests can accurately detect the new coronavirus variant Omicron.

• The Omicron variant has more than 30 mutations in the spike protein alone. 
• Last week, the World Health Organisation (WHO) classified the Omicron variant as a SARS-CoV-2 "variant of concern," saying it may spread more quickly than other forms.
• Thermo Fisher's TaqPath COVID-19 assays can report accurate results even if one of the gene targets is impacted by a mutation.
• Read Next: Thermo Fisher's COVID-19 Response Revenue Accounts For 22% In Q3 Sales, Boosts FY21 Outlook.
• Specific genotyping assays to detect the Omicron variant are being developed for Thermo Fisher's TaqMan Mutation Panel. 
• The panel, which is currently used for research purposes, already has a menu of over 50 assays to assess confirmed COVID-19 cases for the presence of known variants and mutations.
• Also See: Qiagen Says Its COVID-19 PCR Tests Can Detect The New South African Variant.
• Price Action: TMO shares traded higher by 1.04% at $645.40 during the premarket session on the last check Monday.